Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPrinter
NCT04432207Phase 1Terminated
- Sponsor
- Imugene
- Start
- Nov 2020
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Peptide-based Cancer Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of pd1-vaxx in non-small cell lung cancer (NSCLC) (13 arms), sponsored by Imugene. Primary endpoints: Safety and tolerability of IMU-201 graded per CTCAE version 5.00 at Day 29, Optimal Biological Dose at Day 43 and 1 more. Started Nov 2020; status: terminated.
02
Drugs
pd1-vaxx
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04432207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432207.